Alert detail
LCD L38339: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian
What changed
New assay coverage may influence prostate cancer billing practices.
Who’s affected: Oncology billing teams · Effective: February 5, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 5 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.